Sweden · Delayed Price · Currency is SEK Ambea AB Earnings Call Transcripts
Fiscal Year 2026
-
Q2 delivered 7% net sales growth and 28% higher adjusted EBITA, with all segments contributing and strong cash flow supporting investments and shareholder returns. The pipeline for new care places is robust, and the Humana acquisition is progressing as planned.
-
A recommended offer values Humana at SEK 2.96 billion, combining two leading Nordic care providers to create a broader, more specialized platform. The deal is expected to deliver SEK 120 million in annual cost synergies, be EPS accretive in year one, and close by October, pending regulatory approvals.
-
Strong Q1 2026 results with 16% sales growth, improved margins, and robust organic and acquired expansion. Segment performance was solid across the Nordics, with continued investments in quality, people, and capacity supporting a positive outlook for the year.
Fiscal Year 2025
-
Q4 2025 saw 15% net sales growth, strong cash flow, and continued investments in leadership, IT, and M&A, notably the Validia acquisition. Margins were impacted by integration and startup costs, but financial targets remain intact, with a 20% dividend increase proposed.
-
Q3 2025 saw robust growth with net sales up 16% and EBITDA up 19%, driven by acquisitions and organic expansion. Margin and cash flow targets were exceeded, and the company strengthened its Nordic presence, especially in Finland, while launching a major share buyback.
-
Net sales grew 16% year-over-year, driven by acquisitions and organic growth, with all financial targets met for the first time. Segment performance was strong across the Nordics, and further M&A and organic expansion are expected, especially in Finland and Denmark.
-
Q1 2025 saw 5% net sales growth and a 10% rise in EBITDA, driven by organic expansion and acquisitions, notably Validia in Finland. Segment performance was strong overall, with some margin pressure in Nutida, and robust cash flow supported dividends, M&A, and buybacks.
-
The acquisition of Validia provides a strategic entry into Finland, expanding the group’s Nordic footprint and offering a platform for future growth. Financial terms include a EUR 126 million enterprise value, limited cost synergies, and integration by 2026. Seller retains a stake, supporting ongoing alignment.
Fiscal Year 2024
-
Q4 2024 saw 7% net sales growth and a 20% EBITDA increase, with strong operational improvements and robust cash flow. Segment performance was solid, especially in Vardaga and Altiden, and the company remains well below leverage targets while pursuing further acquisitions.
-
Q3 2024 saw 6% net sales growth and a 25% EBITDA increase, driven by higher occupancy, new contracts, and acquisitions. Strong cash flow supported dividends, buybacks, and debt reduction, while new Danish legislation and ongoing pipeline expansion position the group for future growth.
-
Q2 2024 saw 6% net sales growth and a 42% EBITDA increase, with strong performance in Vardaga and Stendi, while Altiden and Klara lagged. Free cash flow and margins improved, supporting dividends, acquisitions, and share buybacks. Growth is expected to continue, driven by demand, new units, and M&A.